Arcutis Biotherapeutics Inc (NASDAQ: ARQT) kicked off on Tuesday, down -3.49% from the previous trading day, before settling in for the closing price of $10.88. Over the past 52 weeks, ARQT has traded in a range of $1.76-$13.17.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 303.42%. While this was happening, its average annual earnings per share was recorded 59.98%. With a float of $101.24 million, this company’s outstanding shares have now reached $116.89 million.
Let’s determine the extent of company efficiency that accounts for 296 employees. In terms of profitability, gross margin is 92.17%, operating margin of -136.13%, and the pretax margin is -147.95%.
Arcutis Biotherapeutics Inc (ARQT) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Arcutis Biotherapeutics Inc is 13.39%, while institutional ownership is 99.96%. The most recent insider transaction that took place on Sep 03 ’24, was worth 107,695. Before that another transaction happened on Aug 19 ’24, when Company’s insider sold 1,728 for $8.29, making the entire transaction worth $14,318. This insider now owns 194,859 shares in total.
Arcutis Biotherapeutics Inc (ARQT) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.36 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 59.98% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 9.80% during the next five years compared to -48.07% drop over the previous five years of trading.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Trading Performance Indicators
Take a look at Arcutis Biotherapeutics Inc’s (ARQT) current performance indicators. Last quarter, stock had a quick ratio of 8.19. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.29.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.18, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach -1.15 in one year’s time.
Technical Analysis of Arcutis Biotherapeutics Inc (ARQT)
Looking closely at Arcutis Biotherapeutics Inc (NASDAQ: ARQT), its last 5-days average volume was 1.59 million, which is a drop from its year-to-date volume of 3.63 million. As of the previous 9 days, the stock’s Stochastic %D was 81.84%. Additionally, its Average True Range was 0.73.
During the past 100 days, Arcutis Biotherapeutics Inc’s (ARQT) raw stochastic average was set at 63.02%, which indicates a significant decrease from 74.06% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 97.07% in the past 14 days, which was higher than the 77.08% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.71, while its 200-day Moving Average is $7.68. However, in the short run, Arcutis Biotherapeutics Inc’s stock first resistance to watch stands at $10.96. Second resistance stands at $11.42. The third major resistance level sits at $11.76. If the price goes on to break the first support level at $10.16, it is likely to go to the next support level at $9.82. Should the price break the second support level, the third support level stands at $9.36.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Key Stats
The company with the Market Capitalisation of 1.23 billion has total of 115,764K Shares Outstanding. Its annual sales at the moment are 59,610 K in contrast with the sum of -262,140 K annual income. Company’s last quarter sales were recorded 30,860 K and last quarter income was -52,330 K.
